TY - JOUR
T1 - Mutational analysis of PTEN/PIK3CA/AKT pathway in oral squamous cell carcinoma
AU - Cohen, Yoram
AU - Goldenberg-Cohen, Nitza
AU - Shalmon, Bruria
AU - Shani, Tali
AU - Oren, Shirley
AU - Amariglio, Ninette
AU - Dratviman-Storobinsky, Olga
AU - Shnaiderman-Shapiro, Anna
AU - Yahalom, Ran
AU - Kaplan, Ilana
AU - Hirshberg, Abraham
N1 - Funding Information:
This research was supported by The Legacy Heritage Clinical Research Initiative of the Israel Science Foundation (Y.C.– Grant No. 1716/08 ), and in part by the Israel Cancer Association (Grant No. 20100092 ) and by the Ernst and Tova Turnheim (Nee Alexandrovitz) Clinical Research Fund in Dentistry.
PY - 2011/10/1
Y1 - 2011/10/1
N2 - The phosphoinositide 3-kinase (PI3K)/v-akt murine thymoma (AKT) viral oncogene pathway is involved in regulating the signaling of multiple biological processes such as apoptosis, metabolism, cell proliferation, and cell growth. Mutations in the genes associated with the PI3K/AKT pathway including PI3K, AKT, RAS and PTEN, are infrequently found within head and neck squamous cell carcinoma and more specifically are rarely reported in oral squamous cell carcinoma (OSCC) cases. We aimed to investigate the frequency of mutations in AKT1, PTEN, PIK3CA, and RAS (K-RAS, N-RAS, H-RAS) genes in 37 cases of oral squamous cell carcinoma (OSCC). Mutational analysis of PTEN, RAS, PIK3CA and AKT genes was performed using chip-based matrix-assisted laser desorption time-of-flight (MALDI-TOF) mass spectrometry and by direct sequencing. The only gene mutated in our series was the PIK3CA. Missense mutations of the PIK3CA gene were found in 4 of our cases (10.8%); no correlation has been found with oral location, stage and survival. The absence of mutations in AKT1, PTEN, and RAS genes in the present study is in accordance with previous studies confirming that these genes are rarely mutated in OSCC. Our data confirm that PIK3CA is important to OSCC tumorigenesis and can contribute to oncogene activation of the PIK3CA/AKT pathway in OSCC. The knowledge of the PIK3CA's involvement in OSCC is important because a specific kinase inhibitor could be considered as a future therapeutic option for OSCC patients with PIK3CA mutations.
AB - The phosphoinositide 3-kinase (PI3K)/v-akt murine thymoma (AKT) viral oncogene pathway is involved in regulating the signaling of multiple biological processes such as apoptosis, metabolism, cell proliferation, and cell growth. Mutations in the genes associated with the PI3K/AKT pathway including PI3K, AKT, RAS and PTEN, are infrequently found within head and neck squamous cell carcinoma and more specifically are rarely reported in oral squamous cell carcinoma (OSCC) cases. We aimed to investigate the frequency of mutations in AKT1, PTEN, PIK3CA, and RAS (K-RAS, N-RAS, H-RAS) genes in 37 cases of oral squamous cell carcinoma (OSCC). Mutational analysis of PTEN, RAS, PIK3CA and AKT genes was performed using chip-based matrix-assisted laser desorption time-of-flight (MALDI-TOF) mass spectrometry and by direct sequencing. The only gene mutated in our series was the PIK3CA. Missense mutations of the PIK3CA gene were found in 4 of our cases (10.8%); no correlation has been found with oral location, stage and survival. The absence of mutations in AKT1, PTEN, and RAS genes in the present study is in accordance with previous studies confirming that these genes are rarely mutated in OSCC. Our data confirm that PIK3CA is important to OSCC tumorigenesis and can contribute to oncogene activation of the PIK3CA/AKT pathway in OSCC. The knowledge of the PIK3CA's involvement in OSCC is important because a specific kinase inhibitor could be considered as a future therapeutic option for OSCC patients with PIK3CA mutations.
KW - AKT
KW - Head and neck cancer
KW - Oral cancer
KW - Oral squamous cell carcinoma
KW - PI3K
KW - PTEN
KW - RAS
UR - http://www.scopus.com/inward/record.url?scp=80054001986&partnerID=8YFLogxK
U2 - 10.1016/j.oraloncology.2011.07.013
DO - 10.1016/j.oraloncology.2011.07.013
M3 - Article
C2 - 21824802
AN - SCOPUS:80054001986
SN - 1368-8375
VL - 47
SP - 946
EP - 950
JO - Oral Oncology
JF - Oral Oncology
IS - 10
ER -